# Implantable biosensors for chronic disease Surgically or subcutaneously implanted sensors that continuously monitor a chronic-disease parameter for months to years without an external wearable — implantable continuous glucose monitors and insertable cardiac monitors — distinct from external wearables and ingested/swallowed sensors: Senseonics' Eversense 365 in the US, Medtronic's LINQ II and Boston Scientific's LUX-Dx cardiac monitors in the US, Biotronik's BIOMONITOR in Germany, and MicroPort in China. Source: https://en.bioecon.ru/technology/implantable-biosensors-chronic-disease/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: MDR 2017/745 | OECD: Biotech-health | Regulator: FDA (USA), EMA (European Union), NMPA (China)] Implantable biosensors for chronic disease are surgically or subcutaneously placed sensors that continuously monitor a physiological parameter for months to years, distinct from an external wearable device or a swallowed ingestible sensor. Senseonics' Eversense 365 recently launched in Europe following European approval as the world's first and only one-year continuous glucose monitor (CGM), with real-world evidence presented at the ADA and ATTD conferences demonstrating sustained performance and positive patient impact throughout a full year of wear in both open- and closed-loop insulin-delivery systems. Medtronic's LINQ II insertable cardiac monitor has cleared multiple FDA 510(k) submissions for continuous arrhythmia detection. Boston Scientific's LUX-Dx insertable cardiac monitor line has also cleared multiple FDA 510(k)s, though the company issued an FDA recall in 2026 for a LUX-Dx II monitoring-system malfunction. Biotronik's BIOMONITOR IV, its newest insertable cardiac monitor, adds artificial-intelligence-assisted arrhythmia detection, building on the company's record as the first to implant a leadless pacemaker in the US. In China, MicroPort participates in the country's growing implantable cardiac and biosensor monitoring device market. The key directions of implantable biosensors for chronic disease are: 1. **Implantable continuous glucose monitoring (Implantable CGM):** a subcutaneously placed fluorescence-based glucose sensor providing months-to-year-long continuous readings without sensor replacement — Senseonics' Eversense 365. 2. **Insertable cardiac monitors (Insertable Cardiac Monitors):** small subcutaneous devices continuously recording cardiac rhythm to detect intermittent arrhythmia over months to years — Medtronic LINQ II, Boston Scientific LUX-Dx, Biotronik BIOMONITOR. 3. **AI-enabled arrhythmia detection (AI Arrhythmia Detection):** machine-learning algorithms applied to continuous cardiac rhythm data to improve arrhythmia-detection accuracy and reduce false alerts — Biotronik BIOMONITOR IV. 4. **Domestic implantable monitoring devices (Domestic Implantable Monitoring):** regionally manufactured and regulated implantable cardiac/biosensor devices serving a domestic market — MicroPort. ### Sectoral value chain ``` [sensor/device design] ──> [regulatory clearance (FDA 510(k)/MDR/NMPA)] ──> [minimally invasive implantation] │ (continuous physiological monitoring) │ ▼ [clinical alert, intervention & device replacement] <─── [data transmission & remote monitoring] <─────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Sensor/Device Design** | engineering the implantable sensor chemistry/electronics and its biocompatible housing for long-term in-body placement | **In:** target physiological parameter, biocompatible materials.
**Out:** implantable sensor device. | | **Regulatory Clearance** | FDA 510(k)/PMA, EU MDR CE marking, or NMPA registration of the implantable device | **In:** clinical performance/safety data.
**Out:** cleared/CE-marked/registered implant. | | **Minimally Invasive Implantation** | a brief in-clinic procedure places the sensor subcutaneously or surgically | **In:** cleared device, patient procedure.
**Out:** implanted, active sensor. | | **Continuous Monitoring** | the implant continuously measures the target parameter (glucose, cardiac rhythm) over months to years | **In:** implanted sensor.
**Out:** continuous physiological data stream. | | **Data Transmission & Remote Monitoring** | a wearable or bedside transmitter relays sensor data to the patient's app and the clinical monitoring platform | **In:** sensor data stream.
**Out:** remotely accessible patient data. | | **Clinical Alert, Intervention & Replacement** | abnormal readings trigger a clinical alert/intervention, and the device is replaced or removed at end of battery/sensor life | **In:** monitoring data, alert threshold.
**Out:** clinical action or device replacement. | Cross-cutting technologies of the sector: - **Fluorescence-based implantable glucose sensing (Implantable CGM):** a subcutaneous fluorescent polymer sensor continuously measures interstitial glucose, read externally by a transmitter, extending sensor life to a full year in Senseonics' Eversense 365. - **Subcutaneous cardiac rhythm recording (Insertable Cardiac Monitors):** a small, leadless device implanted just under the skin continuously records cardiac electrical activity to catch intermittent arrhythmias that a short-duration Holter monitor would miss. - **AI-assisted signal classification (AI Arrhythmia Detection):** machine-learning models applied to continuous cardiac rhythm data distinguish true arrhythmia events from noise/artifact, reducing false alerts sent to the clinical team. --- ## US The US anchors the deepest implantable-biosensor device bench, spanning implantable CGM and insertable cardiac monitors from the sector's largest medtech companies. ### Eversense 365, LINQ II, LUX-Dx, FDA - **Senseonics:** its Eversense 365 recently launched in Europe following European approval as the world's first and only one-year CGM, with real-world evidence at ADA and ATTD demonstrating sustained performance throughout a full year of wear. - **Medtronic:** its LINQ II insertable cardiac monitor has cleared multiple FDA 510(k) submissions for continuous subcutaneous arrhythmia detection. - **Boston Scientific:** its LUX-Dx insertable cardiac monitor line has cleared multiple FDA 510(k)s, though the company issued an FDA recall in 2026 addressing a LUX-Dx II monitoring-system malfunction. - **FDA framework:** implantable cardiac monitors clear the FDA predominantly via 510(k) submissions, with the category subject to post-market surveillance and recall processes when device malfunctions are identified. --- ## CN China participates in the growing implantable cardiac and biosensor monitoring device market through domestic medtech manufacturers including MicroPort. ### MicroPort, NMPA - **MicroPort:** participates in China's growing implantable cardiac and biosensor monitoring device market as part of its broader medical-device portfolio. - **NMPA framework:** implantable biosensor devices in China register with NMPA as Class III medical devices, the highest-risk regulatory tier given their invasive, long-term in-body placement. --- ## EU Germany anchors Europe's implantable cardiac-monitoring capacity through Biotronik, alongside Senseonics' European launch of its implantable CGM. ### BIOMONITOR, Eversense 365, MDR - **Biotronik (Berlin, Germany):** its BIOMONITOR IV insertable cardiac monitor adds artificial-intelligence-assisted arrhythmia detection, building on the company's record as the first to implant a leadless pacemaker in the US. - **Senseonics' European launch:** Eversense 365 launched in Europe following European regulatory approval as the world's first and only one-year CGM, extending the implantable-CGM category into the EU market. - **MDR framework:** implantable biosensors sold in the EU require conformity assessment and CE marking under the Medical Device Regulation (MDR 2017/745), the highest-scrutiny device class given long-term implantation. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Senseonics** | 🇺🇸 USA | *Eversense 365 implantable CGM* | World's first/only one-year CGM | commercial | | **Medtronic** | 🇺🇸 USA | *LINQ II insertable cardiac monitor* | Multiple FDA 510(k) clearances | commercial | | **Boston Scientific** | 🇺🇸 USA | *LUX-Dx insertable cardiac monitor* | FDA-cleared; 2026 malfunction recall | commercial | | **Biotronik** | 🇩🇪 Germany | *BIOMONITOR IV insertable cardiac monitor* | AI-assisted arrhythmia detection | commercial | | **MicroPort** | 🇨🇳 China | *Implantable cardiac/biosensor devices* | Domestic medtech manufacturer | commercial | --- ## Tech stack and innovations The stack pairs a biocompatible implantable sensor with wireless data transmission and, increasingly, on-device or cloud AI signal processing to extend monitoring duration and improve detection accuracy over external alternatives. 1. **Implantable fluorescence-based glucose sensing (Implantable CGM):** - Senseonics' Eversense 365 uses a subcutaneous fluorescent polymer sensor read externally by a transmitter, extending continuous glucose monitoring to a full year without sensor replacement — the longest duration in the CGM category. 2. **Subcutaneous cardiac rhythm monitoring (Insertable Cardiac Monitors):** - Medtronic's LINQ II, Boston Scientific's LUX-Dx and Biotronik's BIOMONITOR all implant a small, leadless device just under the skin to continuously record cardiac electrical activity over months to years, catching intermittent arrhythmias a short Holter-monitor window would miss. 3. **AI-assisted arrhythmia classification (AI Arrhythmia Detection):** - Biotronik's BIOMONITOR IV applies artificial-intelligence-assisted signal classification to continuous cardiac data, aiming to distinguish true arrhythmia events from noise and reduce false clinical alerts. 4. **Domestic implantable device manufacturing (Domestic Implantable Monitoring):** - MicroPort manufactures implantable cardiac and biosensor monitoring devices for China's domestic market as part of its broader medical-device portfolio. --- ## Value chains and production pipelines ### Industrial pipeline of an implantable biosensor (FDA 510(k)/PMA / EU MDR 2017/745) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Sensor/device design │ ───> │ 2. Regulatory clearance │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Continuous monitoring │ <─── │ 3. Minimally invasive │ │ │ │ implantation │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Data transmission & │ ───> │ 6. Clinical alert, │ │ remote monitoring │ │ intervention & replace │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Sensor and device design The implantable sensor's chemistry or electronics (fluorescent glucose polymer, cardiac electrode) and its biocompatible housing are engineered for long-term placement inside the body without triggering rejection or degradation. #### Stage 2: Regulatory clearance The device clears FDA 510(k) or PMA review, EU MDR conformity assessment and CE marking, or NMPA Class III medical-device registration, each requiring clinical performance and safety data given the invasive, long-duration implantation. #### Stage 3: Minimally invasive implantation A brief in-clinic procedure places the sensor subcutaneously (cardiac monitors, Eversense 365) or via a similarly minor surgical step, typically completed in minutes without general anesthesia. #### Stage 4: Continuous monitoring The implanted sensor continuously measures its target parameter — interstitial glucose or cardiac electrical activity — over the device's full operational life, up to a full year for Eversense 365 or several years for cardiac monitors. #### Stage 5: Data transmission and remote monitoring A wearable or bedside transmitter relays the sensor's data stream to the patient's smartphone app and to the clinical remote-monitoring platform, enabling continuous oversight without in-person visits. #### Stage 6: Clinical alert, intervention and replacement Abnormal readings trigger a clinical alert and possible intervention (insulin-dose adjustment, arrhythmia treatment), and the device is replaced or removed at the end of its sensor or battery life — annually for Eversense 365, or after several years for cardiac monitors, with post-market surveillance addressing any device malfunctions like Boston Scientific's 2026 LUX-Dx II recall.